Table 1.
Patient characteristics.
| CCRT alone (n=58) | CCRT+ICI (n=43) | P | |
|---|---|---|---|
| Age (year) | 0.159 | ||
| ≤59 | 35 (60.3%) | 19 (44.2%) | |
| >59 | 23 (39.7%) | 24 (55.8%) | |
| Sex | 0.402 | ||
| female | 4 (6.9%) | 6 (14.0%) | |
| male | 54 (93.1%) | 37 (86.0%) | |
| ECOG | 0.001 | ||
| 0 | 8 (13.8%) | 19 (44.2%) | |
| 1 | 50 (86.2%) | 24 (55.8%) | |
| Smoking history | 0.066 | ||
| no | 18 (31.0%) | 22 (51.2%) | |
| yes | 40 (69.0%) | 21 (48.8%) | |
| Alcohol history | 0.009 | ||
| no | 14 (24.1%) | 22 (51.2%) | |
| yes | 44 (75.9%) | 21 (48.8%) | |
| Anemia | 0.994 | ||
| no | 46 (79.3%) | 35 (81.4%) | |
| grade I | 12 (20.7%) | 8 (18.6%) | |
| Site | 0.655 | ||
| cervical | 8 (13.8%) | 10 (23.3%) | |
| upper | 21 (36.2%) | 14 (32.6%) | |
| middle | 24 (41.4%) | 15 (34.9%) | |
| distal | 5 (8.6%) | 4 (9.2%) | |
| Length (cm) | 0.837 | ||
| ≤5.55 | 28 (48.3%) | 19 (44.2%) | |
| >5.55 | 30 (51.7%) | 24 (55.8%) | |
| BMI (kg/m2) | 0.209 | ||
| 18.5-24.9 | 37 (63.8%) | 27 (62.8%) | |
| <18.5 | 14 (24.1%) | 6 (14.0%) | |
| >24.9 | 7 (12.1%) | 10 (23.2%) | |
| T stage | 0.327 | ||
| T2 | 5 (8.6%) | 1 (2.3%) | |
| T3 | 37 (63.8%) | 32 (74.4%) | |
| T4 | 16 (27.6%) | 10 (23.3%) | |
| N stage | 0.203 | ||
| N0 | 3 (5.2%) | 6 (14.0%) | |
| N1 | 21 (36.2%) | 20 (46.5%) | |
| N2 | 25 (43.1%) | 12 (27.9%) | |
| N3 | 9 (15.5%) | 5 (11.6%) | |
| AJCC stage | 0.263 | ||
| stage II | 2 (3.5%) | 5 (11.6%) | |
| stage III | 38 (65.5%) | 27 (62.8%) | |
| stage IVa | 18 (31.0%) | 11 (25.6%) | |
| Radiotherapy dose | <0.001 | ||
| 60Gy | 39 (67.2%) | 42 (97.7%) | |
| 50.4Gy | 19 (32.8%) | 1 (2.3%) | |
| Chemotherapy regimen | 0.088 | ||
| TP | 42 (72.4%) | 38 (88.4%) | |
| PF | 16 (27.6%) | 5 (11.6%) |
CCRT, concurrent chemoradiotherapy; ICI, immune checkpoint inhibitors; ECOG, Eastern Cooperative Oncology Group; Hgb, haemoglobin; MBI, body mass index; AJCC, American Joint Committee on Cancer; TP, paclitaxel plus cisplatin; PF, cisplatin plus fluorouracil.